Multidrug resistance phenotype in leukaemic cells from patients with acute myelocytic leukaemia can be detected with 99Tcm-MIBI

British Journal of Cancer

Volumn 77, Issue 11, 1998, Pages 1732-1736

  Gruber, A ^a   Arestrom I ^a   Xu, D ^a   Liliemark, J ^a   Larsson, S A ^a   Jacobsson, H ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

99TcM MIBI; Drug transport; Multidrug resistance; P glycoprotein

Indexed keywords

CYCLOSPORIN A; DAUNORUBICIN; GLYCOPROTEIN P; MESSENGER RNA; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; SCINTIGRAPHY;

DAUNORUBICIN; DRUG RESISTANCE, MULTIPLE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; P-GLYCOPROTEIN; TECHNETIUM TC 99M SESTAMIBI; TUMOR CELLS, CULTURED;

EID: 0031781461     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.290     Document Type: Article

References (30)

1. Arao S, Suwa H, Mandai M, Tashiro H, Miyazaki K, Okamura H, Nomura H, Hiai H and Fukumoto M (1994) Expression of multidrug resistance gene and localization of P-glycoprotein in human primary ovarian cancer. Cancer Res 54: 1355-1359
2. m-sestamibi as an agent for imaging P-glycoprotein-mediated multi-drug resistance: in vitro and in vivo studies in a rat breast tumor cell line and its doxorubicin-resistant variant. Nucl Med Commun 16: 253-257
3. Barrand MA, Rhodes T, Center MS and Twenyyman PR (1993) Chemosensitisation and drug accumulation effects of cyclosporin A, PSC-833, and verapamil in human MDR large cell lung cancer cells expressing a 190k membrane protein distinct from P-glycoprotein. Eur J Cancer 29A: 408-415
4. Baurin R, Zenebergh A and Trout A (1978) Cellular uptake and metabolism of daunorubicin as determined by high-performance liquid chromatography. J Chromatogr 157: 331-336
5. Broxterman HJ, Sonneveld P, Feller N, Ossenkoppele GJ, Währer DCR, Eekman CA, Schoester M, Lankelma J, Pinedo HM, Löwenberg B and Schuurhuis GJ (1996) Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity. Blood 87: 4809-4816
6. Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D and Fiere D (1992) Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 79: 473-476
7. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV and Deeley RG (1992) Overexpression of a transport gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650-1654
8. Fojo AT (1991) Multidrug resistance. Adv Intern Med 36: 195-218
9. Goldstein LJ, Pastan I and Gottesman MM (1992) Multidrug resistance in human cancer. Crit Rev Oncol Hematol 12: 243-253
10. Gruber A, Vitols S, Korgren S, Areström I, Peterson C, Björkholm M, Reizenstein P and Luthman H (1992) Quantitative determination of mdr1 gene expression in leukaemic cells from patients with acute leukaemia. Br J Cancer 66: 266-272
11. Hart SM, Ganeshaguru K, Hoffbrand AV, Prentice HG and Mehta AB (1994) Expression of the multidrug resistance-associated protein (MRP) in acute leukemia. Leukemia 8: 2163-2168
12. Ino T, Miyazaki H, Isogai M, Nomura T, Tsuzuki M, Tsuruo T, Ezaki K and Hirano M (1994) Expression of P-glycoprotein in de novo acute myelogenous leukemia at initial diagnosis: results of molecular and functional assays, and correlation with treatment outcome. Leukemia 8: 1492-1497
13. Kapucu LÖ, Akyuz C, Vural G, Oguz A, Atasever T, Büyükpamukçu M and Ünlü M (1997) Evaluation of therapy response in children with untreated malignant lymphomas using technetium-99m-sestamibi. J Nucl Med 38: 243-247
14. Lee PD, Noble-Topham SE, Bell RS and Andrulis IL (1996) Quantitative analysis of multidrug resistance gene expression in human osteosarcomas. Br J Cancer 74: 1046-1050
15. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen I-M, Head DR, Appelbaum FR and Willman CL (1997) Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 89: 3323-3329
16. Linn SC, Honkoop AH, Hoekman K, Van der Valk P, Pinedo HM and Giaccone G (1996) p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer. Br J Cancer 74: 63-68
17. List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher B, Baier M and Dalton W (1993) Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 11: 1652-1660
18. Luker GD, Fracasso PM, Dobkin J and Piwnica-Worms D (1997) Modulation of the multidrug resistance p-glycoprotein: detection with technelium-99m-sestamibi in vivo. J Nucl Med 38: 369-372
19. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ and Salmon SE (1991) P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 9: 17-24
20. Moretti J-L, Azaloux H, Boisseron D, Koyoumdjian J-C and Vilcoq J (1996) Primary breast cancer imaging with technetium-99m sestamibi and its relation with P-glycoprotein overexpression. Eur J Nucl Med 23: 980-986
21. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA and Croop JM (1993) Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 53: 977-984
22. Piwnica-Worms D, Rao VV, Kronauge JF and Croop JM (1995) Characterization of multidrug resistance P-glycoprotein transport function with an organotechnetium cation. Biochemistry 34: 12210-12220
23. Raderer M and Scheithauer W (1993) Clinical trials of agents that reverse multidrug resistance. Cancer 72: 3553-3563
24. Sarris AH, Younes A, McLaughlin P, Moore D, Hagemeister F, Swan F, Rodriguez MA, Romaguera J, North L, Mansfield P, Callender D, Mesina O and Cabanillas F (1996) Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 14: 233-239
25. Schneider E, Cowan KH, Bader H, Toomey S, Schwartz GN, Karp JE, Burke PJ and Kaufmann SH (1995) Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood 85: 186-193
26. Sonneveld P, Durie BGM, Lokhorst HM, Marie J-P, Solbu G, Suciu S, Zittoun R, Löwenberg B and Nooter K (1992) Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet 340: 255-259
27. Te Boekhorst P, Löwenberg B, Van Kapel J, Nooter K and Sonneveld P (1995) Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia. Leukemia 9: 1025-1031
28. Vecchio SD, Ciarmiello A, Potena MI, Carriero MV, Mainolfi C, Botti G, Thomas R, Cerra M, D'Aiuto G, Tsuruo T and Salvatore M (1997) In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients. Eur J Nucl Med 24: 150-159
29. Xu D, Knaust E, Pisa P, Palucka K, Areström I, Peterson C and Gruber A (1996) Levels of mdr1 and mrp mRNA in leukaemic cell populations from patients with acute myelocytic leukaemia are heterogenous and inversely correlated to cellular daunorubicin accumulation. Br J Haematol 92: 847-854
30. Yuen AR and Sikic BI (1994) Review article. Multidrug resistance in lymphomas. J Clin Oncol 12: 2453-2459